Publications by authors named "Kenneth A Foon"

Claim this Profile
R
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Anthony R Mato, Kenneth A Foon, Tatyana Feldman, Stephen J Schuster, Jakub Svoboda

Am J Hematol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, Ian W Flinn, Andres Forero-Torres, Kenneth A Foon

Leuk Lymphoma· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Mark H Kirschbaum, Kenneth A Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone

Leuk Lymphoma· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel therapies for aggressive B-cell lymphoma.
Kenneth A Foon, Kenichi Takeshita, Pier L Zinzani

Adv Hematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
Kenneth A Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley Marks

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Dhaval R Mehta, Kenneth A Foon, Robert L Redner, Anastasios Raptis, Mounzer Agha

Leuk Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Michael Boyiadzis, Robert L Redner, Anastasios Raptis, Jing-Zhou Hou, Mounzer Agha, Kenneth A Foon

Ann Hematol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.
Lela Kardava, Qi Yang, Anthony St Leger, Kenneth A Foon, Suzanne Lentzsch

Int Immunol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Mary T Litzinger, Kenneth A Foon, Kwong-Yok Tsang, Jeffrey Schlom, Claudia Palena

Leuk Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials.
Kenneth A Foon

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.
Miroslaw J Szczepanski, Marta Szajnik, Ann Welsh, Kenneth A Foon, Theresa L Whiteside

Cancer Immunol Immunother· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Mary T Litzinger, Kenneth A Foon, Helen Sabzevari, Kwong-Yok Tsang, Jeffrey Schlom

Cancer Immunol Immunother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.
Miroslaw J Szczepanski, Marta Szajnik, Malgorzata Czystowska, Magis Mandapathil, Laura Strauss, Kenneth A Foon

Clin Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice.
Asim Saha, Malaya Bhattacharya-Chatterjee, Kenneth A Foon, Esteban Celis, Sunil K Chatterjee

Int J Cancer· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Kenneth A Foon, Michael Boyiadzis, Stephanie R Land, Stanley Marks, Anastasios Raptis

J Clin Oncol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.
Samuel A Jacobs, Steven H Swerdlow, Jeffrey Kant, Kenneth A Foon, Rachel Jankowitz

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approved monoclonal antibodies for cancer therapy.
Michael Boyiadzis, Kenneth A Foon

Expert Opin Biol Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.
Je-Jung Lee, Kenneth A Foon, Robbie B Mailliard, Ravikumar Muthuswamy, Pawel Kalinski

J Leukoc Biol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric immunophenotyping for hematologic neoplasms.
Fiona E Craig, Kenneth A Foon

Blood· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carcinoembryonic antigen transgenic mouse models for immunotherapy and development of cancer vaccines.
Malaya Bhattacharya-Chatterjee, Asim Saha, Kenneth A Foon, Sunil K Chatterjee

Curr Protoc Immunol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.
Michael Boyiadzis, Kenneth A Foon, Steven Pavletic

Expert Opin Biol Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
Smarajit Pal, Asim Saha, Kartik Mohanty, Palash Mallick, Sunil K Chatterjee, Kenneth A Foon

Cancer Biol Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.
Samuel A Jacobs, Kenneth A Foon

Expert Opin Biol Ther· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational research: advancing medical science by stimulating interdisciplinary research.
Kenneth A Foon

Exp Biol Med (Maywood)· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Asim Saha, Sunil K Chatterjee, Kenneth A Foon, Esteban Celis, Malaya Bhattacharya-Chatterjee

Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis